Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype‐4 recurrence post–liver transplantation: A prospective cohort trial

El‐Hamamsy, Manal; Montasser, Iman Fawzy; Mansy, Azza El‐Sayed; Nabet, Dina Ezzeldin; El-Meteini, Mahmoud

doi:10.1111/jcpt.12807

Cited by 2 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCV eradication with DAA before and after LT brought a tremendous improvement in transplantation outcomes[ 47 - 49 ]. The type of post-LT immunosuppression regimen seems not to impact the DAA treatment response[ 50 ], but fluctuation of calcineurin inhibitor trough levels during treatment may account for graft immune-mediated dysfunction[ 51 , 52 ]. Although a similar DAA efficacy might be expected in pediatric LT recipients, no relevant pediatric experience has been published.…”

Section: Hcv Treatment Of Hcv In Children At Riskmentioning

confidence: 99%

Breakthroughs and challenges in the management of pediatric viral hepatitis

Nicastro

Norsa

Giorgio

et al. 2021

WJG

View full text Add to dashboard Cite

Chronic infections by hepatitis B virus (HBV) and hepatitis C virus (HCV) major causes of advanced liver disease and mortality worldwide. Although regarded as benign infections in children, their persistence through adulthood is undoubtedly of concern. Recent advances in HCV treatment have restored the visibility of these conditions and raised expectations for HBV treatment, which is currently far from being curative. Herein we describe direct-acting antivirals available for pediatric HCV (sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) and their real-world use. A critical review of the HBV pediatric classification is provided. Anti-HBV investigational compounds are reviewed in light of the pathophysiology in the pediatric population, including capsid assembly modulators, antigen secretion inhibitors, silencing RNAs, and immune modifiers. Recommendations for screening and management of immunosuppressed children or those with other risk factors or comorbidities are also summarized.

show abstract

Section: Hcv Treatment Of Hcv In Children At Riskmentioning

confidence: 99%

Breakthroughs and challenges in the management of pediatric viral hepatitis

Nicastro

Norsa

Giorgio

et al. 2021

WJG

View full text Add to dashboard Cite

show abstract

Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major

Li¹,

Lu²,

Zhou³

et al. 2021

PGPM

View full text Add to dashboard Cite

Purpose To analyze factors influencing tacrolimus (TAC) trough concentration (C 0 ) in β-thalassemia major (β-TM) pediatric patients after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and to investigate the effects of genotype polymorphism and drug-drug interactions on TAC trough concentration in children with β-TM. Furthermore, to analyze the correlation between TAC C 0 and efficacy and adverse reactions. Patients and Methods Prospectively collection of demographic information and details of combined treatment of patients with β-TM receiving HSCT, and genotypes of CYP3A4, CYP3A5, and ABCB1 (rs1045642, rs1128503, rs2032582) were obtained for each patient. Univariate analysis and multiple linear regression analysis were used to investigate influencing factors on TAC C 0 . The impact of different genotypes and the co-administration of azole antifungal drugs on β-TM patients receiving TAC were evaluated, together with the correlation between acute graft-versus-host disease (aGVHD), infection, and liver injury of TAC C 0 . Results A total of 46 patients with 587 concentration data were included. The multiple linear regression results showed that the patient’s sex, weight, postoperative time, hemoglobin, platelet count, serum cystatin C, and combined voriconazole were independent influencing factors of the infusion trough concentration/daily dose, C 0 /D iv . Age, body surface area, postoperative time, co-administration of voriconazole, and CYP3A4*18B are independent influencing factors of C 0 /D po . Group comparisons showed that voriconazole can affect TAC C 0 administered intravenously (IV) and orally in β-TM pediatric patients, while patient genotype can affect TAC C 0 during oral administration. TAC C 0 does not correlate with aGVHD or liver injury, but infection may be associated with TAC C 0 . Conclusion The concentration of TAC should be closely monitored when co-administered with voriconazole. It is worth considering that the influence of genotype on the trough concentration of oral TAC and individualized drug administration warrant investigation. Finally, this study indicated that C 0 is not suitable as an indicator of the efficacy of TAC.

show abstract

Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype‐4 recurrence post–liver transplantation: A prospective cohort trial

Cited by 2 publications

References 41 publications

Breakthroughs and challenges in the management of pediatric viral hepatitis

Breakthroughs and challenges in the management of pediatric viral hepatitis

Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major

Contact Info

Product

Resources

About